GLPwatch
Bydureon for Parkinson's disease
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCBydureon (exenatide) is not FDA-approved for Parkinson's disease, and any use for this condition is off-label or investigational; listed research includes multiple trials and analyses exploring its potential effects on Parkinson's disease symptoms and progression.
AI summary of the sources below.
| Drug | Bydureon (exenatide) |
|---|---|
| Condition | Parkinson's disease |
| Approval status | Investigational / off-label |
| Research papers | 16 |
Bydureon is not FDA-approved for parkinson's disease; the research below reflects investigational or off-label study only.
Research on exenatide for parkinson's disease (16)
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Exenatide and the treatment of patients with Parkinson's disease.
- Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
- Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
- Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
- What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.
- Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
- Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
- Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.
- Is Exenatide a Treatment for Parkinson's Disease?
- Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
- Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?
- Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson's Disease Mice.
- Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.
- Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson's disease when considering the coexisting effects of diabetes mellitus.
- Exenatide Is Neuroprotective in a New Rabbit Model of Hypoxia-Ischemia.